Cargando…
Real-World Effectiveness and Optimal Dosage of Favipiravir for Treatment of COVID-19: Results from a Multicenter Observational Study in Thailand
Favipiravir is a broad-spectrum oral antiviral agent that shows in vitro activity against SARS-CoV-2. Presently, data on the real-world effectiveness and optimal dosage of favipiravir for treating COVID-19 are limited. We conducted a retrospective observational study of hospitalized adult patients w...
Autores principales: | Rattanaumpawan, Pinyo, Jirajariyavej, Supunnee, Lerdlamyong, Kanokorn, Palavutitotai, Nattawan, Saiyarin, Jatuporn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220013/ https://www.ncbi.nlm.nih.gov/pubmed/35740211 http://dx.doi.org/10.3390/antibiotics11060805 |
Ejemplares similares
-
Epidemiology of Carbapenem-Resistant Enterobacterales Infection and Colonization in Hospitalized Patients at a University Hospital in Thailand
por: Wangchinda, Walaiporn, et al.
Publicado: (2022) -
Effectiveness of Favipiravir monotherapy in the treatment of COVID-19: real world data analysis from Thailand
por: Srisubat, Attasit, et al.
Publicado: (2023) -
SARS-CoV-2 RNA shedding in recovered COVID-19 cases and the presence of antibodies against SARS-CoV-2 in recovered COVID-19 cases and close contacts, Thailand, April-June 2020
por: Chirathaworn, Chintana, et al.
Publicado: (2020) -
Genomic and clinical characterisation of multidrug-resistant carbapenemase-producing ST231 and ST16 Klebsiella pneumoniae isolates colonising patients at Siriraj hospital, Bangkok, Thailand from 2015 to 2017
por: Boonyasiri, Adhiratha, et al.
Publicado: (2021) -
Epidemiology and risk factors of extensively drug-resistant Pseudomonas aeruginosa infections
por: Palavutitotai, Nattawan, et al.
Publicado: (2018)